Background and Aim: Genetic polymorphism has been implicated as a factor for the occurrence of non-alcoholic fatty liver disease (NAFLD). This study attempted to assess whether polymorphisms in the leptin receptor (LEPR) gene and its combined effect with patatin-like phospholipase domain-containing protein 3 (PNPLA3/adiponutrin) are associated with risk of NAFLD. Methods: A total of 144 biopsy-proven NAFLD and 198 controls were genotyped using the Sequenom MassARRAY platform. Results: We observed a significant association between the LEPR rs1137100 and rs1137101 with susceptibility to NAFLD (odds ratio [OR] 1.64, 95% confidence interval [CI] 1.18-2.28, P = 0.003; and OR 1.61, 95% CI 1.11-2.34, P = 0.013, respectively) and to non-alcoholic steatohepatitis (OR 1.49, 95% CI 1.05-2.12, P = 0.026; and OR 1.57, 95% CI 1.05-2.35, P = 0.029, respectively). The LEPR rs1137100 is also associated with simple steatosis (OR 2.27, 95% CI 1.27-4.08, P = 0.006). Analysis of gene-gene interaction revealed a strong interaction between the LEPR and PNPLA3 genes (empirical P = 0.001). The joint effect of LEPR and PNPLA3 greatly exacerbated the risk of NAFLD (OR 3.73, 95% CI 1.84-7.55, P < 0.0001). The G allele of rs1137100 is associated with lower fibrosis score (OR 0.47,, P = 0.001).
Introduction
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming a huge problem globally due to the epidemic of obesity and type 2 diabetes mellitus. 1 NAFLD represents a spectrum of simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis: simple steatosis is generally benign, whereas NASH can potentially progress, leading to liver-related mortality. 2 The interplay between environmental and genetic factors promotes the development and progression of NAFLD. Lifestyle modification has been shown to improve liver histology in NAFLD patients. 3, 4 A report on familial aggregation study that compared overweight children with and without NAFLD indicated that fatty liver was more likely to develop among siblings with NAFLD. 5 While adiponutrin (PNPLA3) has been recognized as a wellestablished NAFLD gene, little is known about the role of leptin receptor (LEPR) in genetic susceptibility to NAFLD. The hypothalamic effects of leptin, the adipocyte-derived hormone, promote modulation of body weight. Leptin acts through leptin receptor, a single-transmembrane-domain receptor of the cytokine-receptor family to control satiety and maintain body's constant energy balance. 6 The notion that the obesity gene LEPR is associated with NAFLD has been pointed by several association studies. 7, 8 Among patients with NAFLD, polymorphism of LEPR was found to be associated with obesity parameters, insulin resistance, and glucose levels. 9 We previously reported a strong association between rs738409 of PNPLA3 gene with susceptibility to NAFLD in all three major ethnic subgroups of the Malaysian population. 10 Each ethnic group has different origin and assumed to have a different genetic pools, therefore providing a good setting to study ethnic differences in susceptibility to NAFLD. The main outcomes of the study were to assess, in the same set of study population, whether the non-synonymous single nucleotide polymorphisms (SNPs) of the LEPR gene, rs1137100 and rs1137101 are associated with severity of NAFLD, and to evaluate the effects of the variants on histological features of NAFLD. We also report a new finding on the interaction of LEPR and PNPLA3 polymorphisms on susceptibility to NAFLD.
Methods
Study population. A study was carried out at the University Malaya Medical Centre (UMMC) on 144 consecutive biopsyproven NAFLD patients and 198 controls without NAFLD according to the criteria stated below. Ethnicity of the subjects was confirmed by affirmations of absence of mixed marriages for at least three generations. NAFLD is confirmed on liver histology and evaluated according to the NASH Clinical Research Network. 11, 12 All the biopsy specimens were on an average 1.5 cm long and contained at least six portal tracts. Exclusion criteria of which all the study subjects had fulfilled included alcohol consumption of > 10 g/day, 13 hepatitis B or C infection, autoimmune hepatitis, been on drugs that are known to cause steatosis, and Wilson's disease. The controls were genetically unrelated healthy subjects with body mass index (BMI) < 25 kg/m 2 , fasting plasma glucose < 110 mg/dL, normal lipid profile, and normal liver enzymes. NAFLD was excluded in the controls by ultrasonography according to the absence of the following criteria; (i) slight diffuse increase in bright homogeneous echoes in the liver parenchyma with normal visualization of the diaphragm and portal and hepatic vein borders, and normal hepatorenal echogenicity contrast; (ii) diffuse increase in bright echoes in the liver parenchyma with slightly impaired visualization of the peripheral portal and hepatic vein borders; (iii) marked increase in bright echoes at a shallow depth with deep attenuation, impaired visualization of the diaphragm, and marked vascular blurring. 14 The study protocol was approved by the Medical Ethics Committee of UMMC, and all subjects provided written informed consent to participate.
Clinical and laboratory assessments. Standard protocol was used to determine the BMI, waist circumference, and blood pressure of the subjects. The biochemical tests for the determination of hemoglobin A1c (HbA1c), total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), alanine transferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGT) level in all subjects were as standard clinical laboratory methods carried out in an accredited laboratory at UMMC.
Genotyping. Genomic DNA was extracted from the collected blood samples using the QiAamp DNA Mini Kit (Qiagen, Hilden, Germany). The quality of DNA was checked each time to ensure that 260/280 and 260/230 absorbance ratios exceed 1.8 to indicate high-quality DNA. The genomic DNA was then diluted to 10 ng/mL and 20 ng/mL, respectively for sample and duplicate sample and then placed in the well. A volume of 1 mL of DNA were used in each amplification reaction. The LEPR rs1137100 and rs1137101 were genotyped at the University of Hong Kong, Genome Research Centre using the Sequenom MassARRAY technology platform with the iPLEX GOLD chemistry (Sequenom, San Diego, CA, USA) according to the manufacturer's protocols. Briefly, MassARRAY AssayDesign software package (v4.0) was used to design the specific assays with proximal SNPs filtering. Quality of the PCR fragment amplification and extension primer specificity was checked prior to running the reaction. Residual nucleotides were dephosphorylated prior the iPLEX Gold reaction. Following a single-base extension, reaction products were desalted with SpectroClean resin (Sequenom), and 10 nL was spotted onto the SpectroCHIP using the MassARRAY Nanodispenser. MassARRAYAnalyzer Compact MALDI-TOF mass spectrometer was used to determine the mass. For proper data acquisition and analysis, the MassARRAY Typer 4.0 software was used. Genotypes were called after cluster analysis using the default setting of Gaussian mixture model. Inspection of the clusters was done to ensure a clear cluster separation with good signal to noise cut-off. A manual review was done to further clarify uncertain genotype calls. Assay with less than 80% call rate within the same SpectroChip was considered failed. A blank and five duplicates were introduced as quality controls. SpectroChip with more than 25% call rate in the blank control or with less than 99.5% concordance in duplicate checks along with more than 10% call rate in blank check were considered to have failed and would be required to be repeated.
Statistical. All statistical analyses were performed using SPSS 16.0 (IBM Corp., Chicago, IL, USA). Data are presented as mean Ϯ standard deviation for continuous and as percentages for categorical. Prior to analyzing, all variables were tested for normality. Independent t-test was used for normally distributed variables (age, BMI, waist circumference, ALT, HDL cholesterol, LDL cholesterol, total cholesterol, triglycerides, and systolic blood pressure) to determine the association between two groups of subjects. Skewed variables (HbA1c, AST, GGT, diastolic blood pressure, steatosis grade, lobular inflammation, ballooning, and fibrosis) were tested using Mann-Whitney U-test.
A goodness-of fit c2 test was used to assess whether each individual variant was in equilibrium at each locus in the population (Hardy-Weinburg equilibrium). A P-value of less than 0.05 indicated a lack of agreement with the equilibrium. Allelic association was performed using logistic regression. Stepwise regression analysis indicated that there was a significant effect of ethnicity but no significant effect of age and gender on the association. The potential effect of ethnicity on susceptibility to NAFLD was therefore adjusted using multiple logistic regression. The calibration and fit of the model were assessed using Hosmer Lemeshow goodness of fit and receiver operating characteristic (ROC) curves. ANOVA and Kruskal-Wallis test were performed for comparison of three groups.
Both the univariate and multivariate analysis of association of genotypes and histological ordinal variables were performed using Jonckheere-Terpstra test and ordinal regression. Multivariate analysis took into account the adjustment of other histological features. False discovery rate (FDR) was applied to correct for testing for multiple histological parameters using BenjaminiHochberg procedure. 15 The Generalized Multifactor Dimensionality Reduction (GMDR) method was employed to investigate the influence of gene-gene interaction on NAFLD. 16 A 10-fold cross validation with exhaustive search that considered all possible combinations was selected. Ethnicity was first determined as a covariate in the analysis. Permutation testing based on 1000 shuffles was performed to obtain empirical P-value and confirmed using logistic regression model.
A calculated sample size of 118 cases and 162 controls was to provide a desired power of 80% at a of 0.05 with the following assumptions: the allele frequency range from 0.20-0.80, the baseline risk for the Malaysian population was 0.17, and the minimum detectable odds ratio was 2.0.
Results
Genotypes and allele frequencies of LEPR polymorphisms. The demographic and clinical characteristics of the NAFLD and control groups are described in Table 1 . The clinical data of the simple steatosis and NASH patients are presented in Table 2 . Table 3 shows the allele frequencies and association between LEPR SNPs with NAFLD. The genotypes of each SNPs were in Hardy-Weinburg equilibrium. There is a significant association observed for both rs1137100 and rs1137101 with susceptibility to NAFLD (odds ratio [OR] 1.64, 95% confidence interval [CI] 1.18-2.28, P = 0.003; and OR 1.61, 95% CI 1.11-2.34, P = 0.013, respectively). The association is also observed for rs1137100 in the Malays after ethnic stratification (OR 2.18, 95% CI 1.21-3.95, P = 0.010). However, no association is found in all the three ethnic subgroups studied for rs1137101.
Patients with NAFLD were then stratified into simple steatosis (n = 33) and NASH (n = 111) following which, association analysis was performed (Table 3) . Both SNPs were associated with NASH (OR 1.49, 95% CI 1.05-2.12, P = 0.026; and OR 1.57, 95% CI 1.05-2.35, P = 0.029, respectively). However, only rs1137100 is found to be associated with simple steatosis (OR 2.27, 95% CI 1.27-4.08, P = 0.006). NASH patients were further stratified into two groups; NASH without significant fibrosis (fibrosis score < 2) and NASH with significant fibrosis (fibrosis score Ն 2). We observed a significant association with NASH without significant fibrosis for rs1137100 (OR 2.18, 95% CI 1.24-3.84, P = 0.007).
The polymorphism of the rs1137100 was earlier found to be associated with simple steatosis (fatty liver) in the Malays. We continued the analysis by comparing the distribution of various clinical and histological parameters among the three major ethnic subgroups ( Table 4 ). The parameters that are associated with NAFLD such as BMI, AST, and ALT enzymes were found to be the highest in the Malays as compared to the Chinese and Indians (P < 0.05).
LEPR polymorphisms and liver histology. Next, we investigated the distribution of various clinical and histological parameters of NAFLD among the genotypes of LEPR rs1137100 and rs1137101. However, only rs1137100 showed a significant difference between the genotypes with fibrosis stage (P = 0.004) but not with other clinical and histological features. Genotype GG is significantly associated with decreased fibrosis score (patients with genotype GG compared to AA, had mean score of 1.48 vs 2.29). For the purpose of determining the magnitude of effect of allele G with fibrosis score, univariate and multivariate analysis were performed (Table 5) . A single allele G of rs1137100 in an individual is found to be protective against fibrosis (OR 0.47, 95% CI 0.28-0.78, P = 0.001). The association remained significant even after the adjustment of other histological features (P < 0.001). However, no association was found between the G allele of rs1137100 with steatosis, lobular inflammation, and hepatocellular ballooning.
LEPR and PNPLA3 gene interaction. Functionally, both LEPR and PNPLA3 genes play important roles in lipid regulation. We therefore performed an analysis to find out whether there is an interaction between the two genes on susceptibility to NAFLD. The results of the gene-gene interaction analysis are demonstrated in Table 6 . There are two best combinations (two locus and three locus) yielded by the analysis. Both two-locus and three-locus models have a perfect cross-validation consistency and similar testing accuracy. Investigation of the gene-gene interaction on the susceptibility to NAFLD identified a significant effect of LEPR rs1137100 and PNPLA3 rs738409 interaction (empirical P = 0.001 and empirical P = 0.011, for rs1137100 and rs1137101, respectively). The best GMDR model suggested for the interaction was the two-locus model. The significant interaction was confirmed by logistic regression (P < 0.0001). We further evaluated the effect of combined alleles from each variant of the two different genes, LEPR rs1137100 and PNPLA3 rs738409 and tested as follows; two risk factors versus one risk factor versus no risk factor. The risk of NAFLD is first to be noted as 1.64 for LEPR rs1137100 and 2.23 for PNPLA3 rs738409. Although not shown in the table, it is noteworthy that the risk of NAFLD increased to 3.73 with the combined effect of risk allele of both SNPs (OR 3.73, 95% CI 1.84-7.55, P < 0.0001).
Statistical power. The power for the significant associations is shown to be 92%, 85%, 60%, 85%, 66%, 79%, and 93%, for rs1137100 with NAFLD, rs1137101 with NAFLD, rs1137100 with NAFLD in Malay, rs1137100 with simple steatosis, rs1137100 with NASH, rs1137101 with NASH, and rs1137100 with NASH without significant fibrosis, respectively.
Discussion
This study showed significant association between both the LEPR rs1137100 and rs1137101 with susceptibility to NAFLD. Our results suggest that in patients with NAFLD, the G allele of rs1137100 is associated with a less severe form of liver disease. To our knowledge, the current study is the first to report an interaction between LEPR and PNPLA3 genes with increased risk of NAFLD compared to either gene alone.
The data to date, on the relationship between the LEPR gene variants, rs1137100 and rs1137101, and obesity is conflicting. No significant association was found between rs1137100 with obesity. 17, 18 Although several studies have reported an association between rs1137101 with obesity, 18, 19 an equal number of negative studies have also been reported. 20, 21 A recent meta-analysis of the LEPR tag SNPs did not show an overall association with obesity. 22 The discrepancy of these findings may be explained by the differences in allele frequency across ethnic groups. Ethnicity could act as a significant effect modifier thereby explaining the conflicting observations. 23 In the present study, we showed that the polymorphisms on the LEPR, rs1137100 and rs1137101, are associated with increased risk of NAFLD and NASH. The rs1137100 was also shown to be associated with simple steatosis and NASH without significant fibrosis. The G allele frequency of rs1137100 in the control subjects was 0.78 for the Chinese and 0.19 for the Indian, which was almost the same as that reported in the HapMap database but higher than that in other populations (such as European and African American).
An interesting finding from this study is the association of the G allele with NASH without significant fibrosis but not with NASH with significant fibrosis, suggesting that the polymorphism of LEPR rs1137100 is associated with lower fibrosis score, and patients with G allele are protected against higher stage of fibrosis Ն 2. These findings suggest that rs1137100, specifically the G allele, is associated with a milder form of liver disease in patients with NAFLD. To date, there has been no published report of an association between LEPR rs1137100 G allele and liver fibrosis. Our study is the first to provide this association finding and the availability of histological profile of the liver samples made this possible, which is a major strength of this study. Hepatic fibrosis score was found to be higher in subjects with metabolic syndrome. 24 In a Taiwanese Han population, lower metabolic risk was reported in those bearing the GG genotype. 25 A Japanese study in obese children showed a significantly lower total and LDL cholesterol in subjects with GG genotype. 26 Leptin level has been shown to correlate with metabolic syndrome profile such as adipocity and insulin resistance. 27, 28 It was reported that leptin level was significantly greater in subjects with AA genotype than G allele carriers. 29 Hence, these studies suggest that LEPR rs1137100 G allele is associated with a lower metabolic risk.
This study indicated nearly three-fold increased risk of NAFLD by the combined effect of the SNPs of LEPR with PNPLA3 compared to either gene alone. A common variant in the PNPLA3 gene (rs738409) was found to be associated with hepatic fat content and confers risk of NAFLD in the Dallas Heart Study of different ancestries; Hispanics, European-Americans and African Americans. 30 Subsequently, a number of replicated studies on PNPLA3 in various populations have been carried out, and interestingly, all yielded a positive association including that of our own population. 10, [31] [32] [33] [34] [35] [36] [37] [38] The effect size of NAFLD is increased with a single variant of LEPR or PNPLA3. The risk of NAFLD is however increased dramatically with the coexistence of both variants of LEPR and PNPLA3, suggesting a possible positive interaction between the two genes. Investigation of gene interaction between LEPR and PNPLA3 is therefore a good approach that allows us to understand the genetic interaction of the two genes that encode for products that are important in lipid regulation and within same study population.
Analysis of interaction between LEPR and PNPLA3 gene revealed a strong interaction between LEPR (rs1137100) and PNPLA3 (rs738409) SNPs on NAFLD susceptibility. The pleiotropic actions of leptin via leptin receptor help suppress food intake, a mechanism involved in appetite control and body weight regulation. 6 Adiponutrin (PNPLA3) exerts its effect in response to food intake, in which it is highly upregulated in response to feeding and downregulated in fasting state, displaying its role in lipid storage in the liver. 39 Both genes are correlatively upregulated in a state of excess lipid.
There are several limitations and strengths that can be derived from the present study. Most of the studies have only looked at the association of NAFLD per se but not with the complete spectrum of NAFLD that comprises of simple steatosis, NASH without significant fibrosis and NASH with significant fibrosis. Liver biopsy remains the gold standard to define the NAFLD spectrum. The need for histological confirmation of NAFLD limits the sample size in our NAFLD cohort. Further stratification of the NAFLD patients into simple steatosis and NASH could have resulted in some of the findings to be underpowered. However, we were able to obtain the desired statistical power of > 80% in the main association results; association with NAFLD, with simple steatosis, and with NASH without significant fibrosis. Since liver biopsy was not performed in the controls due to ethical considerations, the selection of the controls is very crucial. The control subjects have normal BMI, fasting plasma glucose, lipid profile, and liver enzymes to reduce the likelihood of misclassifying the controls. However, we cannot rule out mild steatosis among the controls. A major strength of this study was the ability to compare the association between LEPR polymorphisms and NAFLD among three major ethnic groups in Malaysia, which are also the main ethnic groups in Asia. 40 This study suggest that the rs1137100 and rs1137101 of the LEPR is associated with susceptibility to NAFLD. This study is also the first to report the genetic interaction between the LEPR and the much reported PNPLA3 gene on NAFLD susceptibility.
In conclusion, we are able to show that the LEPR SNPs render our population susceptible to NAFLD. The LEPR rs1137100 G allele was associated with lower fibrosis score and a less severe form of liver disease in patients with NAFLD. This study suggests that the combined effect of variants of LEPR and PNPLA3 confer increased susceptibility to NAFLD. A larger sample size and more ethnically diverse samples are needed to replicate these findings.
